Aurinia Pharmaceuticals

AUPH · Nasdaq · Canada

Share price · AUPH

$15.13-0.17 (-1.11%) 3M

close as of 2026-11-18 · 24h delayed · vol 762K (0.8x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when AUPH's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 20 Aug 2026+6.8%
  2. 6 Aug 2026+6.2%
  3. 1 Jul 2026-6.9%
  4. 25 Jun 2026-5.7%

    Nothing announced by AUPH that day or the session before.

  5. 7 May 2026-6.8%
  6. 1 Apr 2026+4.4%
  7. 4 Mar 2026+6.3%

    Nothing announced by AUPH that day or the session before.

  8. 3 Dec 2025-6.3%

    Nothing announced by AUPH that day or the session before.

Share of unusual movement by asset

For each asset, the share of AUPH's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Voclosporin (Lupkynis)
events and moves
6shown from 8 days
aritinercept
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—5%
Other company news (earnings, financing, releases naming no asset)—26%
Sessions with no dated event—69%

Assets

(2 total)
2Total Assets
1Approved
0Phase 3 / Filed
1Phase 1–2 / Early
3Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Voclosporin(Lupkynis)
Approved
Calcineurin · Cyclophilin A (leading to calcineurin inhibition)Small molecule
Systemic Lupus ErythematosusLupus Nephritis
Phase 1/2
BAFF / APRILProtein / enzyme therapeutic
Systemic Lupus ErythematosusMyasthenia Gravis
Generalized Myasthenia Gravis

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
March 2029 (1)
aritinerceptPhase 1/2Myasthenia Gravis, Generalized
Est. primary completion 2029-03-02 · NCT07596901 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (21)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$84M$17M$46M+ $441M short-term inv.—$46M operating cash flowreport ↗
View 20 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$83M$13M$180M+ $263M short-term inv.—$53M operating cash flowreport ↗
2026-Q1$78M$7.5M$379M—report ↗
2025-Q4$77M—$80M+ $318M short-term inv.—$46M operating cash flowreport ↗
2025-Q3$73M$8.4M$73M+ $279M short-term inv.—$44M operating cash flowreport ↗
2025-Q2$70M$7.4M$53M+ $262M short-term inv.—$44M operating cash flowreport ↗
2025-Q1$62M$5.7M$66M+ $246M short-term inv.—$1.3M operating cash flowreport ↗
2024-Q4$60M—$83M+ $275M short-term inv.—$30M operating cash flowreport ↗
2024-Q3$68M$3.0M$37M+ $312M short-term inv.—$17M operating cash flowreport ↗
2024-Q2$57M$4.1M$33M+ $297M short-term inv.—$16M operating cash flowreport ↗
2024-Q1$50M$5.5M$64M+ $255M short-term inv.$11M-$19M operating cash flowreport ↗
2023-Q4$45M—$49M+ $302M short-term inv.$27M$14M operating cash flowreport ↗
2023-Q3$55M$14M$46M+ $292M short-term inv.$13M-$13M operating cash flowreport ↗
2023-Q2$41M$13M$82M+ $269M short-term inv.$11M-$2.8M operating cash flowreport ↗
2023-Q1$34M$13M$89M+ $273M short-term inv.$26M-$32M operating cash flowreport ↗
2022-Q4$28M—$94M+ $295M short-term inv.$26M$10M operating cash flowreport ↗
2022-Q3$56M$11M$86M+ $291M short-term inv.$9.0M-$15M operating cash flowreport ↗
2022-Q2$28M$12M$152M+ $240M short-term inv.$36M-$28M operating cash flowreport ↗
2022-Q1$22M$13M$133M+ $286M short-term inv.$38M-$47M operating cash flowreport ↗
2021-Q4$23M—$232M+ $234M short-term inv.$33M-$26M operating cash flowreport ↗
2021-Q3$15M$20M$58M$50M-$40M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$283M$33M$80M+ $318M short-term inv.—$136M operating cash flowreport ↗

For full-year 2025, Aurinia reported total revenue of $283.06M, up 20.4% YoY, and net income of $287.2M. R&D spend was $32.51M, up 56.4% YoY, while cash and equivalents stood at $80.21M at year-end; no quarterly net burn was disclosed.

The company guided 2026 total revenue to $315M–$325M (up 11%–15% YoY) and LUPKYNIS net product sales to $305M–$315M (up 12%–16% YoY). It also reported progress on aritinercept, having initiated a clinical study in one autoimmune disease and planning another in the first half of 2026, and disclosed a share repurchase of 12.2 million common shares for $98.2 million during 2025.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$235M$21M$83M+ $275M short-term inv.—$44M operating cash flowreport ↗
2023-FY$176M$50M$49M+ $302M short-term inv.$20M-$33M operating cash flowreport ↗
2022-FY$134M$45M$94M+ $295M short-term inv.$27M-$80M operating cash flowreport ↗
2021-FY$46M$51M$232M+ $234M short-term inv.$45M-$158M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 11 purchases ($25.1M), 3 sales ($736K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-11-13Robertson Stephen P. · Chief Legal OfficerOpen-market sale11,867$15.97$190KForm 4
2026-09-10Robertson Stephen P. · Chief Legal OfficerOpen-market sale11,939$15.95$190KForm 4
2026-08-21Robertson Stephen P. · Chief Legal OfficerOpen-market sale20,975$16.97$356KForm 4
2026-06-04Bailey Jeffrey Allen · directorAward / grant (derivative)23,931——Form 4
2026-06-04Nova Tina Susan · directorAward / grant (derivative)23,931——Form 4
2026-06-04Goetz Kathleen · directorAward / grant (derivative)23,931——Form 4
2026-06-04Johnson Craig A · directorAward / grant (derivative)23,931——Form 4
2026-06-02TANG KEVIN; TANG CAPITAL MANAGEMENT LLC · director, Chief Executive Officer, 10% owner; 10% ownerOpen-market purchase206,005$15.28$3.1MForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 257 reporting institutions held 73.9M shares ($1.1B).

#InstitutionSharesValue
1TANG CAPITAL MANAGEMENT LLC12,229,500$181.2M
2BlackRock, Inc.7,845,521$116.3M
3NEA Management Company, LLC3,969,834$58.8M
4TWO SIGMA INVESTMENTS, LP3,428,705$50.8M
5ARROWSTREET CAPITAL, LIMITED PARTNERSHIP3,284,368$48.7M
6STATE STREET CORP2,527,099$37.5M
7MORGAN STANLEY2,232,548$33.1M
8MARSHALL WACE, LLP1,874,597$27.8M
9RENAISSANCE TECHNOLOGIES LLC1,663,835$24.7M
10D. E. Shaw & Co., Inc.1,572,983$23.3M
11GEODE CAPITAL MANAGEMENT, LLC1,536,009$22.8M
12GOLDMAN SACHS GROUP INC1,433,508$21.2M
13VANGUARD PORTFOLIO MANAGEMENT LLC1,256,361$18.6M
14JACOBS LEVY EQUITY MANAGEMENT, INC1,097,189$16.3M
15NOMURA HOLDINGS INC968,910$14.4M